Prescient completes integration of Uptake and Dolon under single global brand

Prescient completes integration of Uptake and Dolon under single global brand

 

  • Announcement follows the acquisition of commercial healthcare consultancy, Uptake and the value pricing and access consultancy, Dolon

  • Prescient is the strategy-to-impact partner for life sciences companies 

  • Together, the team comprises over 550 pharmaceutical experts across commercial, competitive strategy, medical affairs, and value, pricing and access. 

 

London, UK - 13 August 2026 – Healthcare consultancy Prescient Healthcare Group has completed the integration of recently acquired businesses Uptake and Dolon under a single global Prescient brand, creating an organisation of more than 550 specialists supporting life sciences companies across commercial strategy, competitive intelligence, medical affairs, and value, pricing and access.

 

The rebrand marks the final stage of integrating the three businesses following Prescient's acquisitions of Uptake and Dolon, providing clients with a single point of access to expertise spanning the pharmaceutical product lifecycle.

 

Jason McKenna, Chief Executive Officer of Prescient, said: "What began as an expansion of our capabilities has become something much more powerful," said Jason McKenna, Chief Executive Officer of Prescient. "Over the past several months, the Prescient, Dolon and Uptake teams have been working together to solve increasingly complex challenges for clients.  Bringing everything together under the Prescient name reflects how the platform works today, as one integrated organisation combining specialist expertise across commercial, medical and market access disciplines."

 

The unified business supports pharmaceutical and biotechnology companies from early clinical development through product launch and lifecycle management. Prescient said the integrated structure enables multidisciplinary teams to address increasingly connected commercial, scientific and market access challenges facing the industry.

 

The move also simplifies how clients engage with the business, bringing together capabilities across:

  • Commercial Strategy and Planning

  • Competitive Strategy

  • Medical Affairs and Real-World Evidence

  • Value, Pricing and Access

 

Debbie Allman, Prescient’s Chief Growth Officer and Global Practice Lead, Commercial, added: "Our clients don't experience challenges in functional silos. Scientific, commercial, competitive and access decisions increasingly influence one another. Our role is to connect those perspectives in practical ways that help clients make stronger decisions and execute with confidence."

 

The integration follows a period of operational alignment between the three organisations and establishes a single global Prescient brand across its seven international offices.

 

ENDS.

 

About Prescient

Prescient is the strategy-to-impact partner for life sciences companies.

 

We help clients cut through complexity, build connected strategies, and turn stronger decisions into measurable business impact across the lifecycle. Bringing together deep expertise across Commercial, Competitive Strategy, Medical Affairs, and Value, Pricing & Access, Prescient combines scientific, market and stakeholder perspectives to help clients see further, go deeper and deliver impact where it counts.

 

Prescient’s continued international growth is supported by its existing investor Bridgepoint, which partnered with the company in 2021 via Bridgepoint Development Capital, a lower middle-market fund focused on supporting fast-growing businesses across Europe.

 

For more information, visit www.prescienthg.com 


Media Contact

Amelia Hutchins, Global Marketing Director

ahutchins@prescienthg.com